Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico reiterates an Outperform rating on Travere Therapeutics (NASDAQ:TVTX) and maintains a $13 price target.
April 17, 2024 | 5:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico reiterates an Outperform rating on Travere Therapeutics with a $13 price target.
The reiteration of an Outperform rating and maintenance of a $13 price target by a reputable analyst like Laura Chico from Wedbush is likely to instill confidence among investors and could positively influence the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100